Neuronetics, Inc. (STIM) News

Neuronetics, Inc. (STIM): $3.16

0.07 (+2.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter STIM News Items

STIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

STIM News Highlights

  • For STIM, its 30 day story count is now at 2.
  • Over the past 13 days, the trend for STIM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest STIM News From Around the Web

Below are the latest news stories about NEURONETICS INC that investors may wish to consider to help them evaluate STIM as an investment opportunity.

Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatmentMALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced upgrades today to the TrakStar® platform that will o

Yahoo | September 26, 2022

Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony

The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for Mental Health NeuroStar University in Charlotte, North Carolina The first NeuroStar University Class in Charlotte, North Carolina MALVERN, Pa., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients

Yahoo | September 13, 2022

Is Neuronetics (NASDAQ:STIM) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | August 30, 2022

Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health

Latest NeuroStar innovation to simplify the motor threshold determination for cliniciansMALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitm

Yahoo | August 29, 2022

Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Yahoo | August 8, 2022

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material ind

Yahoo | August 5, 2022

Canaccord Genuity Keeps Their Buy Rating on Neuronetics (STIM)

In a report released yesterday, William Plovanic from Canaccord Genuity reiterated a Buy rating on Neuronetics (STIM – Research Report), with a price target of $9.00. The company's shares closed last Tuesday at $4.25. According to TipRanks.com, Plovanic is a 3-star analyst with an average return of 1.6% and a 47.1% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Edwards Lifesciences, and TransMedics Group. Currently, the analyst consensus on Neuronetics is a Strong Buy with an average price target of $10.50, a 143.6% upside from current levels.

Christine Brown on TipRanks | August 3, 2022

Neuronetics, Inc. (STIM) Q2 2022 Earnings Call Transcript

Good morning, and thank you for joining us for Neuronetics' second quarter 2022 conference call. Joining me on today's call are Neuronetics' president and chief executive officer, Keith Sullivan; and SVP, chief financial officer, and treasurer, Steve Furlong. For a discussion of risks and uncertainties associated with Neuronetics' business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the company's annual report on Form 10-K and Form 10-Q, which will be filed later today.

Yahoo | August 3, 2022

Neuronetics (STIM) Gets a Hold Rating from BTIG

E ratio of -3.28.

Brian Anderson on TipRanks | August 2, 2022

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6181 seconds.